Get the Stockscreener App
5.50
1.91%
-0.09
Annexon Inc stock is traded at $5.50, with a volume of 138.02K.
It is down -1.91% in the last 24 hours and down -2.61% over the past month.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
See More
Previous Close:
$5.59
Open:
$5.48
24h Volume:
138.02K
Relative Volume:
0.05
Market Cap:
$815.34M
Revenue:
-
Net Income/Loss:
$-134.24M
P/E Ratio:
-3.1073
EPS:
-1.77
Net Cash Flow:
$-121.34M
1W Performance:
+1.91%
1M Performance:
-2.61%
6M Performance:
+152.67%
1Y Performance:
+98.66%
1-Day Range:
$5.39
$5.59
1-Week Range:
$5.12
$5.73
52-Week Range:
$1.285
$7.18
Annexon Inc Stock (ANNX) Company Profile
Name
Annexon Inc
Sector
Industry
Phone
(650) 822-5500
Address
1400 SIERRA POINT PARKWAY, BRISBANE
Compare ANNX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
5.47 | 833.22M | 0 | -134.24M | -121.34M | -1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.32 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
767.10 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
735.42 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.74 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
294.65 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-01-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-23 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-30-23 | Initiated | Wells Fargo | Overweight |
| May-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| May-25-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-16-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | BTIG Research | Buy |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Sep-23-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-26-21 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | BofA Securities | Buy |
| Aug-18-20 | Initiated | Cowen | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
View All
Annexon Inc Stock (ANNX) Latest News
Annexon (ANNX) CFO Lew sells shares to cover RSU tax withholding - Stock Titan
Annexon, Inc. (ANNX) CMO sells shares to cover tax obligations - Stock Titan
Annexon (ANNX) EVP Overdorf sells shares to cover RSU tax - Stock Titan
Annexon (ANNX) EVP sells 5,566 shares to cover RSU tax withholding - Stock Titan
Annexon Spotlights GA Phase III, GBS Regulatory Plans and ANX1502 Update at TD Cowen Conference - MarketBeat
ANNX: Late-stage neuroinflammatory programs near key data and filings, with strong commercial focus - TradingView
Director files sale notice for 5,566 ANNX shares (NASDAQ: ANNX) - Stock Titan
ANNX (NASDAQ: ANNX) Rule 144 notice shows 5,894 shares to be sold; prior 5,290 sold - Stock Titan
ANNX (NASDAQ) Rule 144: Insider sale of 6,225 shares; 4,339 vested - Stock Titan
ANNX (NASDAQ: ANNX) Form 144 lists 5,565-share notice and recent insider sale - Stock Titan
Annexon, Inc. (NASDAQ:ANNX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
ANNX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Annexon Showcases Promising Drug Ahead of Pivotal Trial Data - StocksToTrade
Annexon Showcases Emerging Treatment with Topline Data on Horizon - timothysykes.com
ANNX Technical Analysis & Stock Price Forecast - Intellectia AI
Annexon Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
Does Annexon Inc. meet Warren Buffett’s criteriaEarnings Performance Report & Weekly Watchlist for Consistent Profits - mfd.ru
ANNX (NASDAQ: ANNX) insider sale notice: 5,820 shares tied to vesting - Stock Titan
Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference - Investing News Network
Annexon (ANNX) CFO receives 250,000 options and 62,500 RSUs in equity grant - Stock Titan
Annexon (ANNX) grants CMO 225,000 options and 56,250 RSUs - Stock Titan
Jamie Dananberg Sells 5,290 Shares of Annexon (NASDAQ:ANNX) Stock - MarketBeat
Insider Selling: Annexon (NASDAQ:ANNX) EVP Sells 5,290 Shares of Stock - MarketBeat
Annexon (NASDAQ:ANNX) EVP Sells $40,149.27 in Stock - MarketBeat
Annexon (NASDAQ:ANNX) CFO Sells $40,118.61 in Stock - MarketBeat
Annexon (ANNX) EVP sells 7,857 shares to cover RSU tax withholding - Stock Titan
Will Annexon Inc benefit from government policyTrade Volume Summary & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Aug Spikes: Will Annexon Inc benefit from government policyJuly 2025 PreEarnings & Technical Pattern Based Signals - baoquankhu1.vn
Published on: 2026-02-21 08:39:55 - baoquankhu1.vn
Is Annexon Inc stock a good dividend stock2025 Biggest Moves & High Return Trade Opportunity Guides - baoquankhu1.vn
[144] Annexon, Inc. SEC Filing - Stock Titan
Annexon Biosciences Announces Planned Retirement of Board Chairman - TipRanks
Annexon, Inc. Announces Retirement of Chairman of the Board Thomas G. Wiggans - marketscreener.com
Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy - The Manila Times
Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - Quantisnow
FMR LLC Reduces Stake in Annexon Inc: A Strategic Portfolio Adju - GuruFocus
Aug Decliners: What are the risks of holding Annexon IncJuly 2025 WrapUp & Safe Swing Trade Setup Alerts - baoquankhu1.vn
A Pivotal Year Ahead for Annexon’s Clinical Ambitions - AD HOC NEWS
Annexon, Inc. (NASDAQ:ANNX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Macro Review: Is Annexon Inc in a bullish channel2025 Price Targets & Low Drawdown Momentum Ideas - baoquankhu1.vn
Dow Update: Can Annexon Inc reach all time highs this yearIPO Watch & Growth Focused Stock Reports - baoquankhu1.vn
Market Recap: Will Annexon Inc benefit from government policyJuly 2025 Reactions & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Breakout Watch: Will Annexon Inc benefit from government policyDay Trade & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
VIX Spike: Will CYBN stock recover after earnings2025 Support & Resistance & Detailed Earnings Play Strategies - baoquankhu1.vn
Annexon, Inc. $ANNX Stake Cut by J. Safra Sarasin Holding AG - MarketBeat
Bank of America Securities Reaffirms Their Buy Rating on Annexon Biosciences (ANNX) - The Globe and Mail
Investment Recap: Can HSCS sustain its profitability2025 Investor Takeaways & Daily Profit Maximizing Tips - baoquankhu1.vn
Analyst Downgrade: Will Annexon Inc stock benefit from M AJuly 2025 PostEarnings & Real-Time Volume Triggers - baoquankhu1.vn
Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases - Seeking Alpha
Annexon stock hits 52-week high at 7.1 USD By Investing.com - Investing.com Nigeria
Annexon stock hits 52-week high at 7.1 USD - Investing.com
Annexon Inc Stock (ANNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):